Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-11-04

FDA Approved: NEVANAC — Supplemental Application (Harrow Eye, LLC)

View source ↗

Summary

The FDA approved a supplemental application for NEVANAC (nepafenac) submitted by Harrow Eye, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nevanac (nepafenac)

Snippet

SUPPL AP for NEVANAC (NEPAFENAC)